ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 222 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,775,573 | -24.7% | 638,866 | -2.6% | 0.13% | -15.5% |
| Q2 2023 | $30,266,124 | +38.9% | 656,105 | +20.7% | 0.16% | +32.5% |
| Q1 2023 | $21,796,435 | -5.1% | 543,552 | +9.7% | 0.12% | -5.6% |
| Q4 2022 | $22,958,368 | +51.6% | 495,540 | +35.5% | 0.12% | +61.0% |
| Q3 2022 | $15,145,000 | -3.2% | 365,713 | +39.5% | 0.08% | +5.5% |
| Q2 2022 | $15,643,000 | -23.0% | 262,201 | -6.3% | 0.07% | +12.3% |
| Q1 2022 | $20,317,000 | -17.7% | 279,773 | -4.7% | 0.06% | +4.8% |
| Q4 2021 | $24,681,000 | -5.9% | 293,500 | +0.9% | 0.06% | -1.6% |
| Q3 2021 | $26,239,000 | +43.8% | 290,923 | +52.0% | 0.06% | +46.5% |
| Q2 2021 | $18,253,000 | -8.2% | 191,432 | +9.7% | 0.04% | -17.3% |
| Q1 2021 | $19,876,000 | -24.1% | 174,564 | -7.8% | 0.05% | -23.5% |
| Q4 2020 | $26,201,000 | +22.6% | 189,273 | -27.2% | 0.07% | +9.7% |
| Q3 2020 | $21,376,000 | +32.5% | 260,082 | +26.1% | 0.06% | +17.0% |
| Q2 2020 | $16,138,000 | -32.7% | 206,321 | -61.8% | 0.05% | 0.0% |
| Q1 2020 | $23,982,000 | +339.0% | 539,766 | +322.0% | 0.05% | +165.0% |
| Q4 2019 | $5,463,000 | +6.2% | 127,909 | +6.4% | 0.02% | 0.0% |
| Q3 2019 | $5,145,000 | -33.9% | 120,264 | -1.9% | 0.02% | -33.3% |
| Q2 2019 | $7,785,000 | -36.9% | 122,604 | -31.1% | 0.03% | -38.8% |
| Q1 2019 | $12,347,000 | +42.3% | 178,008 | -10.8% | 0.05% | +22.5% |
| Q4 2018 | $8,675,000 | -48.5% | 199,515 | -9.6% | 0.04% | -36.5% |
| Q3 2018 | $16,850,000 | -6.3% | 220,721 | -5.6% | 0.06% | -16.0% |
| Q2 2018 | $17,981,000 | +3.9% | 233,915 | -31.0% | 0.08% | -6.2% |
| Q1 2018 | $17,298,000 | -4.2% | 339,245 | -12.8% | 0.08% | -1.2% |
| Q4 2017 | $18,053,000 | -7.7% | 389,236 | +6.0% | 0.08% | -11.0% |
| Q3 2017 | $19,550,000 | -6.6% | 367,068 | +8.9% | 0.09% | -9.0% |
| Q2 2017 | $20,938,000 | +23.9% | 337,115 | +35.2% | 0.10% | +19.0% |
| Q1 2017 | $16,900,000 | +158.8% | 249,338 | +168.5% | 0.08% | +133.3% |
| Q4 2016 | $6,529,000 | +67.7% | 92,864 | +69.2% | 0.04% | +80.0% |
| Q3 2016 | $3,893,000 | +13.0% | 54,876 | -22.1% | 0.02% | +11.1% |
| Q2 2016 | $3,444,000 | -52.4% | 70,407 | -38.4% | 0.02% | -51.4% |
| Q1 2016 | $7,238,000 | -41.3% | 114,325 | +3.9% | 0.04% | -38.3% |
| Q4 2015 | $12,340,000 | +10.5% | 110,004 | -5.1% | 0.06% | -1.6% |
| Q3 2015 | $11,169,000 | +26.4% | 115,969 | +34.3% | 0.06% | +52.5% |
| Q2 2015 | $8,839,000 | +74.2% | 86,330 | +5.7% | 0.04% | +73.9% |
| Q1 2015 | $5,073,000 | +52.9% | 81,698 | +8.1% | 0.02% | +43.8% |
| Q4 2014 | $3,317,000 | – | 75,595 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |